Specialist preclinical contract research organisation (CRO) Cellomatics Biosciences has heralded the start of its next successful phase with four promotions and eight new arrivals.
Dr Shailendra Singh, CEO of Cellomatics Biosciences, comments: “Capitalising on our existing strengths and internal team expertise, we intend to further consolidate our position as a specialist biology CRO by broadening and deepening our service offerings in 2024. With these new appointments and internal restructuring, we are poised to catapult ourselves to the next phase of our growth journey.”